Early Detection of Neuropathy in ATTRv

Completed

Conditions studied: Hereditary Amyloidosis, Transthyretin-Related

In brief

The purpose of the study is to evaluate and compare different tools that are used to detect evidence of peripheral neuropathy in patients with TTRv.

Key facts

Study ID

NCT05311488

Run by

University of Pennsylvania

People needed

47

Starts

2022-02-14

Expected to finish

2026-02-14

Last updated by the study team

2026-03-12

Who can join

Age: 30 and older, up to 90. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Patients with known TTR mutations and neuropathy
• Patients with TTR mutation and no symptoms within less than 10 years of typical onset of disease
• Age criteria must meet the following:
• Non V122I mutations, Age 40 or older.
• V122 I mutations, 55 or older.
• Healthy persons without neuropathy
• The following distribution of age ranges will be considered when enrolling healthy participants:
• 5 patients age 30-40
• 5 patients age 40-50
• 5 patients age 50-60
• 5 patients age 60-70
• Healthy control subjects for this study are defined as subjects with no symptoms of neuropathy or risk factors for neuropathy such as family history of hereditary neuropathy, chemotherapy, diabetes, autoimmune disease, or vitamin deficiency. Their status will be verified by medical records review.

You may not qualify if…

• Patients with neuropathy other than TTR amyloid
• Subjects with risk factors for neuropathy (diabetes, history of neuropathy in the family, neurotoxic drugs) or with neurological disorder associated with elevated NFL

Where it is running

• University of Pennsylvania — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.